Tuberculosis Vaccine is a vaccine primarily used against tuberculosis. Tuberculosis is a serious infection, which affects the lungs and sometimes other parts of the body, such as the bones, joints and kidneys. The bacille Calmette-Gu茅rin (BCG) vaccine has existed for 80 years and is one of the most widely used of all current vaccines, reading >80% of neonates and infants in countries where it is part of the national childhood immunization programme.
The global BCG and Tuberculosis Vaccine market was valued at US$ 76 million in 2023 and is anticipated to reach US$ 93 million by 2030, witnessing a CAGR of 3.0% during the forecast period 2024-2030.
The tuberculosis (TB) vaccination market is driven by the global efforts to combat TB and the increasing burden of the disease in high-risk populations. TB is a highly contagious bacterial infection that poses a significant public health challenge worldwide. Vaccination against TB, primarily through the Bacille Calmette-Gu茅rin (BCG) vaccine, is essential in reducing TB incidence and severity, especially in endemic regions. The rise in TB cases and drug-resistant strains contribute to market growth as governments and healthcare organizations focus on prevention strategies. Moreover, advancements in vaccine research and development, including novel TB vaccines under investigation, have the potential to further improve TB control efforts. However, the market also faces challenges, including the variable efficacy of the BCG vaccine against different forms of TB and the need for improved vaccine coverage in high-burden areas. Additionally, addressing vaccine supply and distribution challenges and ensuring equitable access to TB vaccination can pose obstacles for comprehensive disease control. To succeed, companies must focus on research and development to offer innovative TB vaccine candidates, collaborate with global health initiatives to promote vaccination campaigns, and address the challenges to meet the increasing demand for effective TB prevention solutions.
This report aims to provide a comprehensive presentation of the global market for BCG and Tuberculosis Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding BCG and Tuberculosis Vaccine.
Report Scope
The BCG and Tuberculosis Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global BCG and Tuberculosis Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the BCG and Tuberculosis Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Japan BCG Lab
Serum Institute of India
AJ Vaccines
BioFarma
GreenSignal Bio Pharma
China National Biotec
Biomed Lublin
Taj Pharmaceuticals
Ataulpho de Paiva
IVAC-Institute of Vaccines and Medical Biologicals
Queen Saovabha Mem. Inst
Microgen
Segment by Type
Immune Vaccine
Therapy Vaccine
Segment by Application
Self-Procurement
UNICEF
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of BCG and Tuberculosis Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of BCG and Tuberculosis Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 BCG and Tuberculosis Vaccine Market Overview
1.1 Product Overview and Scope of BCG and Tuberculosis Vaccine
1.2 BCG and Tuberculosis Vaccine Segment by Type
1.2.1 Global BCG and Tuberculosis Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 Immune Vaccine
1.2.3 Therapy Vaccine
1.3 BCG and Tuberculosis Vaccine Segment by Application
1.3.1 Global BCG and Tuberculosis Vaccine Market Value by Application: (2024-2030)
1.3.2 Self-Procurement
1.3.3 UNICEF
1.3.4 Others
1.4 Global BCG and Tuberculosis Vaccine Market Size Estimates and Forecasts
1.4.1 Global BCG and Tuberculosis Vaccine Revenue 2019-2030
1.4.2 Global BCG and Tuberculosis Vaccine Sales 2019-2030
1.4.3 Global BCG and Tuberculosis Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 BCG and Tuberculosis Vaccine Market Competition by Manufacturers
2.1 Global BCG and Tuberculosis Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global BCG and Tuberculosis Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global BCG and Tuberculosis Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global BCG and Tuberculosis Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of BCG and Tuberculosis Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of BCG and Tuberculosis Vaccine, Product Type & Application
2.7 BCG and Tuberculosis Vaccine Market Competitive Situation and Trends
2.7.1 BCG and Tuberculosis Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest BCG and Tuberculosis Vaccine Players Market Share by Revenue
2.7.3 Global BCG and Tuberculosis Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 BCG and Tuberculosis Vaccine Retrospective Market Scenario by Region
3.1 Global BCG and Tuberculosis Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global BCG and Tuberculosis Vaccine Global BCG and Tuberculosis Vaccine Sales by Region: 2019-2030
3.2.1 Global BCG and Tuberculosis Vaccine Sales by Region: 2019-2024
3.2.2 Global BCG and Tuberculosis Vaccine Sales by Region: 2025-2030
3.3 Global BCG and Tuberculosis Vaccine Global BCG and Tuberculosis Vaccine Revenue by Region: 2019-2030
3.3.1 Global BCG and Tuberculosis Vaccine Revenue by Region: 2019-2024
3.3.2 Global BCG and Tuberculosis Vaccine Revenue by Region: 2025-2030
3.4 North America BCG and Tuberculosis Vaccine Market Facts & Figures by Country
3.4.1 North America BCG and Tuberculosis Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America BCG and Tuberculosis Vaccine Sales by Country (2019-2030)
3.4.3 North America BCG and Tuberculosis Vaccine Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe BCG and Tuberculosis Vaccine Market Facts & Figures by Country
3.5.1 Europe BCG and Tuberculosis Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe BCG and Tuberculosis Vaccine Sales by Country (2019-2030)
3.5.3 Europe BCG and Tuberculosis Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific BCG and Tuberculosis Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific BCG and Tuberculosis Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific BCG and Tuberculosis Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific BCG and Tuberculosis Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America BCG and Tuberculosis Vaccine Market Facts & Figures by Country
3.7.1 Latin America BCG and Tuberculosis Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America BCG and Tuberculosis Vaccine Sales by Country (2019-2030)
3.7.3 Latin America BCG and Tuberculosis Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa BCG and Tuberculosis Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa BCG and Tuberculosis Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa BCG and Tuberculosis Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa BCG and Tuberculosis Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global BCG and Tuberculosis Vaccine Sales by Type (2019-2030)
4.1.1 Global BCG and Tuberculosis Vaccine Sales by Type (2019-2024)
4.1.2 Global BCG and Tuberculosis Vaccine Sales by Type (2025-2030)
4.1.3 Global BCG and Tuberculosis Vaccine Sales Market Share by Type (2019-2030)
4.2 Global BCG and Tuberculosis Vaccine Revenue by Type (2019-2030)
4.2.1 Global BCG and Tuberculosis Vaccine Revenue by Type (2019-2024)
4.2.2 Global BCG and Tuberculosis Vaccine Revenue by Type (2025-2030)
4.2.3 Global BCG and Tuberculosis Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global BCG and Tuberculosis Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global BCG and Tuberculosis Vaccine Sales by Application (2019-2030)
5.1.1 Global BCG and Tuberculosis Vaccine Sales by Application (2019-2024)
5.1.2 Global BCG and Tuberculosis Vaccine Sales by Application (2025-2030)
5.1.3 Global BCG and Tuberculosis Vaccine Sales Market Share by Application (2019-2030)
5.2 Global BCG and Tuberculosis Vaccine Revenue by Application (2019-2030)
5.2.1 Global BCG and Tuberculosis Vaccine Revenue by Application (2019-2024)
5.2.2 Global BCG and Tuberculosis Vaccine Revenue by Application (2025-2030)
5.2.3 Global BCG and Tuberculosis Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global BCG and Tuberculosis Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck BCG and Tuberculosis Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Merck BCG and Tuberculosis Vaccine Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 Japan BCG Lab
6.2.1 Japan BCG Lab Corporation Information
6.2.2 Japan BCG Lab Description and Business Overview
6.2.3 Japan BCG Lab BCG and Tuberculosis Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Japan BCG Lab BCG and Tuberculosis Vaccine Product Portfolio
6.2.5 Japan BCG Lab Recent Developments/Updates
6.3 Serum Institute of India
6.3.1 Serum Institute of India Corporation Information
6.3.2 Serum Institute of India Description and Business Overview
6.3.3 Serum Institute of India BCG and Tuberculosis Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Serum Institute of India BCG and Tuberculosis Vaccine Product Portfolio
6.3.5 Serum Institute of India Recent Developments/Updates
6.4 AJ Vaccines
6.4.1 AJ Vaccines Corporation Information
6.4.2 AJ Vaccines Description and Business Overview
6.4.3 AJ Vaccines BCG and Tuberculosis Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 AJ Vaccines BCG and Tuberculosis Vaccine Product Portfolio
6.4.5 AJ Vaccines Recent Developments/Updates
6.5 BioFarma
6.5.1 BioFarma Corporation Information
6.5.2 BioFarma Description and Business Overview
6.5.3 BioFarma BCG and Tuberculosis Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 BioFarma BCG and Tuberculosis Vaccine Product Portfolio
6.5.5 BioFarma Recent Developments/Updates
6.6 GreenSignal Bio Pharma
6.6.1 GreenSignal Bio Pharma Corporation Information
6.6.2 GreenSignal Bio Pharma Description and Business Overview
6.6.3 GreenSignal Bio Pharma BCG and Tuberculosis Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 GreenSignal Bio Pharma BCG and Tuberculosis Vaccine Product Portfolio
6.6.5 GreenSignal Bio Pharma Recent Developments/Updates
6.7 China National Biotec
6.6.1 China National Biotec Corporation Information
6.6.2 China National Biotec Description and Business Overview
6.6.3 China National Biotec BCG and Tuberculosis Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 China National Biotec BCG and Tuberculosis Vaccine Product Portfolio
6.7.5 China National Biotec Recent Developments/Updates
6.8 Biomed Lublin
6.8.1 Biomed Lublin Corporation Information
6.8.2 Biomed Lublin Description and Business Overview
6.8.3 Biomed Lublin BCG and Tuberculosis Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Biomed Lublin BCG and Tuberculosis Vaccine Product Portfolio
6.8.5 Biomed Lublin Recent Developments/Updates
6.9 Taj Pharmaceuticals
6.9.1 Taj Pharmaceuticals Corporation Information
6.9.2 Taj Pharmaceuticals Description and Business Overview
6.9.3 Taj Pharmaceuticals BCG and Tuberculosis Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Taj Pharmaceuticals BCG and Tuberculosis Vaccine Product Portfolio
6.9.5 Taj Pharmaceuticals Recent Developments/Updates
6.10 Ataulpho de Paiva
6.10.1 Ataulpho de Paiva Corporation Information
6.10.2 Ataulpho de Paiva Description and Business Overview
6.10.3 Ataulpho de Paiva BCG and Tuberculosis Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Ataulpho de Paiva BCG and Tuberculosis Vaccine Product Portfolio
6.10.5 Ataulpho de Paiva Recent Developments/Updates
6.11 IVAC-Institute of Vaccines and Medical Biologicals
6.11.1 IVAC-Institute of Vaccines and Medical Biologicals Corporation Information
6.11.2 IVAC-Institute of Vaccines and Medical Biologicals BCG and Tuberculosis Vaccine Description and Business Overview
6.11.3 IVAC-Institute of Vaccines and Medical Biologicals BCG and Tuberculosis Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.11.4 IVAC-Institute of Vaccines and Medical Biologicals BCG and Tuberculosis Vaccine Product Portfolio
6.11.5 IVAC-Institute of Vaccines and Medical Biologicals Recent Developments/Updates
6.12 Queen Saovabha Mem. Inst
6.12.1 Queen Saovabha Mem. Inst Corporation Information
6.12.2 Queen Saovabha Mem. Inst BCG and Tuberculosis Vaccine Description and Business Overview
6.12.3 Queen Saovabha Mem. Inst BCG and Tuberculosis Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Queen Saovabha Mem. Inst BCG and Tuberculosis Vaccine Product Portfolio
6.12.5 Queen Saovabha Mem. Inst Recent Developments/Updates
6.13 Microgen
6.13.1 Microgen Corporation Information
6.13.2 Microgen BCG and Tuberculosis Vaccine Description and Business Overview
6.13.3 Microgen BCG and Tuberculosis Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Microgen BCG and Tuberculosis Vaccine Product Portfolio
6.13.5 Microgen Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 BCG and Tuberculosis Vaccine Industry Chain Analysis
7.2 BCG and Tuberculosis Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 BCG and Tuberculosis Vaccine Production Mode & Process
7.4 BCG and Tuberculosis Vaccine Sales and Marketing
7.4.1 BCG and Tuberculosis Vaccine Sales Channels
7.4.2 BCG and Tuberculosis Vaccine Distributors
7.5 BCG and Tuberculosis Vaccine Customers
8 BCG and Tuberculosis Vaccine Market Dynamics
8.1 BCG and Tuberculosis Vaccine Industry Trends
8.2 BCG and Tuberculosis Vaccine Market Drivers
8.3 BCG and Tuberculosis Vaccine Market Challenges
8.4 BCG and Tuberculosis Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Merck
Japan BCG Lab
Serum Institute of India
AJ Vaccines
BioFarma
GreenSignal Bio Pharma
China National Biotec
Biomed Lublin
Taj Pharmaceuticals
Ataulpho de Paiva
IVAC-Institute of Vaccines and Medical Biologicals
Queen Saovabha Mem. Inst
Microgen
听
听
*If Applicable.